Oral corticosteroid dosing strategies for post-COVID-19 organising pneumonia: NORCOVID clinical trial.

Publication date: Jul 01, 2026

Organising pneumonia is an interstitial lung disease linked to infections and other conditions. Cryptogenic organising pneumonia is a rarer, idiopathic form. Organising pneumonia has become one of the most frequent respiratory complications following severe acute respiratory syndrome coronavirus 2 pneumonia. Standard treatment involves the use of glucocorticoids. The objective of the study is to determine the optimal dosage of oral corticosteroids for the treatment of this disease. Randomised, open-label, assessor-blinded, parallel-group, single-centre, noninferiority clinical trial with an active control group comparing two oral prednisone regimens. The control group received prednisone 0. 75 mg.kg.day for 4 weeks; 0. 5 mg.kg.day for 4 weeks; 20 mg.day for 4 weeks; 10 mg.day for 6 weeks; or 5 mg.day for 6 weeks (total treatment duration 6 months) and the experimental group prednisone 0. 5 mg.kg.day for 3 weeks; 20 mg.day for 3 weeks; 15 mg.day for 2 weeks; 10 mg.day for 2 weeks; and 5 mg.day for 2 weeks (total treatment duration 3 months). Visits were carried out at baseline and at 3, 6 and 12 months, recording clinical history, physical examination, pulmonary function tests and chest computed tomography. The primary outcome was noninferiority with a margin of 10% in diffusing capacity of the lung for carbon monoxide (D ) at 6 months. 79 patients were randomised according to intention-to-treat group, 40 to the experimental group and 39 to the control group. Mean+/-sd baseline D was 59. 3+/-16. 7% in the experimental group and 55. 5+/-16. 5% in the control group, with mean improvements at 6 months of 11. 7% (95% CI 7. 18-16. 17%) and 12. 8% (95% CI 8. 57-17. 11%) respectively. The difference between groups at 6 months was 1. 23% (95% CI -5. 13-7. 59%), the experimental regimen being noninferior to the control group with the margin of 10%. Patients in the experimental group had fewer than half as many adverse effects as controls: nine (23%) versus 22 (56%) (p=0. 0027). Treatment with oral corticosteroids lasting 3 months (initial dose of prednisone 0. 5 mg.kg.day) may be recommended in patients with post-COVID organising pneumonia.

Open Access PDF

Concepts Keywords
10mgday Clinical
Glucocorticoids Control
Norcovid Corticosteroids
Pneumonia Covid
Tomography Experimental
Group
Lung
Oral
Organising
Pneumonia
Post
Prednisone
Respiratory
Treatment
Trial

Semantics

Type Source Name
disease MESH COVID-19
disease MESH interstitial lung disease
disease MESH infections
disease MESH severe acute respiratory syndrome
disease MESH pneumonia
drug DRUGBANK Prednisone
disease MESH pulmonary function
drug DRUGBANK Carbon monoxide

Original Article

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *